Senseonics (NYSE:SENS) yesterday touted real-world data it said demonstrated the safety and lack of adverse events with its Eversense continuous glucose monitoring system for people with diabetes.
Eversense is a long-term, implantable GCM sensor with a transmitter that sends discreet vibrations to alert users of low or high glucose. The device can be removed, recharged and re-adhered without discarding the sensor.
Data from a two-year post-market registry in Europe showed no serious adverse events and a low rate of related adverse events following multiple sensor insertion and removal cycles.
Get the full story at our sister site, Drug Delivery Business News.